Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:36 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 222 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Emotional Sensitivity test Clear all

Conditions: Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions: Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test; Procedure · Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Palo Alto, California

Conditions: Asthma
Interventions: HFA-152A propellant, HFA-134A propellant; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 3
States / cities: Marlton, New Jersey • Huntersville, North Carolina • San Antonio, Texas

Conditions: Refractory Cancer, Relapsed Cancer
Interventions: Drug Sensitivity Test (DST); Diagnostic Test
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Miami, Florida • Weston, Florida

Conditions: Overweight and Obesity
Interventions: Replace reactive foods with non-reactive foods; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cardiac Events
Interventions: Index Event; Device
Lead sponsor: Beckman Coulter, Inc.; Industry
Eligibility: 23 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Baltimore, Maryland • Detroit, Michigan • Kettering, Ohio

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Honolulu, Hawaii + 3 more

Conditions: Healthy
Interventions: Aspirin ingestion followed by doing a Bleeding Volume Test, Gatorade Placebo followed by Bleeding Volume Test.; Drug · Procedure
Lead sponsor: Klein, Jeffrey A., M.D.; Individual
Eligibility: 18 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Newport Beach, California • San Juan Capistrano, California

Conditions: Hypertension, Hypertension (HTN), Stroke Prevention, Cardiovascular Risk Factor
Interventions: Technology-enabled Telehealth Care Plan, Blood Pressure Monitoring Device, Tenovi Smart Pillbox, Wearable Activity Trackers (Fitbit or Apple Watch), Healthie EHR, Secure Messaging Platforms (TigerConnect, Weave, AirCall), Antihypertensive Medication Management, Statin Medication Management, Antiplatelet or Anticoagulant Therapy, Laboratory Blood Test Collection; Behavioral · Device · Other + 2 more
Lead sponsor: Syntrillo, Inc; Other
Eligibility: 30 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hepatic Cancer
Interventions: Seravue; Diagnostic Test
Lead sponsor: ImCare Biotech; Industry
Eligibility: 21 Years to 84 Years
Enrollment: 1,392 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hyperalgesia
Interventions: Propranolol, Placebo to Match Propranolol, Remifentanil; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 2 Diabetes Mellitus
Interventions: 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Wills Eye; Other
Eligibility: 10 Years to 90 Years
Enrollment: 208 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Dentin Sensitivity
Interventions: Calcium sodium phosphosilicate (CSPS) Toothpaste; Other
Lead sponsor: HALEON; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Diabetes
Interventions: Application Validation; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Parkinson Disease, Multiple System Atrophy, Dementia With Lewy Bodies, Pure Autonomic Failure
Interventions: Skin Biopsy; Diagnostic Test
Lead sponsor: CND Life Sciences; Other
Eligibility: 40 Years to 99 Years
Enrollment: 428 participants
Timeline: 2021 – 2023
U.S. locations: 23
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 19 more

Conditions: Insulin Resistance, Hyperinsulinemia, Obesity, Healthy
Interventions: Insulin regular, 2.0-3.2 mU/m2/min (euinsulinemia), Insulin regular, 32 mU/m2/min (hyperinsulinemia), Octreotide Acetate, 6-45 ng/kg/min, Dextrose 20 % in Water, Glucagon, 0-0.5 ng/kg/min; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Metabolic Syndrome, Lipotoxicity
Interventions: Valsartan, Hydrochlorothiazide; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Convulsion, Non-Epileptic
Interventions: ReACT; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 11 Years to 18 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Lung Cancer
Interventions: erlotinib hydrochloride, gene expression analysis, protein expression analysis, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, needle biopsy; Drug · Genetic · Other + 1 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Best Practice, Exercise Counseling, Exercise Intervention, Magnetic Resonance Imaging, Neuropathy Assessment, Questionnaire Administration; Other · Procedure
Lead sponsor: University of Rochester NCORP Research Base; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 93
States / cities: Fresno, California • Martinez, California • Roseville, California + 70 more

Conditions: Medical Abortion
Interventions: Self-assessment: MLPT, Self-assessment: LSPT; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Obesity
Interventions: Health Smart for Weight Loss; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 100 Years · Female only
Enrollment: 683 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Covid19, Androgen Receptor Gene Overexpression
Interventions: COVID-19 Androgen Sensitivity Test (CoVAST); Genetic
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 90 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Irvine, California

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: Foundation for the National Institutes of Health; Other
Eligibility: 30 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 2
States / cities: Tempe, Arizona • San Antonio, Texas

Search by objective public record fields.

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma

Individualized Treatments in Adults With Relapsed/Refractory Cancers

IgG-mediated Food Test for Weight Loss

MACE CDS Software Master Enrollment Protocol

Use of a Test That Evaluates How the Body Handles Insulin and Glucose

In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction

Syntrillo Telehealth Stroke Risk Reduction Study

Seravue Validation Study for Hepatocellular Carcinoma (HCC) Diagnosis

Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Building a Database of Results From People Without Eye Problems

Real-World Study of a Calcium Sodium Phosphosilicate Anti-Sensitivity Toothpaste for Dentin Hypersensitivity Relief

Validation of the Diabetes Deep Neural Network Score for Diabetes Mellitus Screening

Synuclein-One Study

Graded Insulin Suppression Test P&F

Regression of Fatty Heart by Valsartan Therapy

Retraining and Control Therapy (ReACT): Sense of Control and Symptom Expectations as Targets of a Treatment for PNES

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

Testing the Effects of Exercise on Chemotherapy-Induced Peripheral Neuropathy

Medical Abortion Self-Confirmation (MASC)

Health-Smart for Weight Loss at UF Jax Clinics

COVID-19 In-vitro Diagnostic Test and Androgen Receptor Gene Expression

Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus